



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Adrenaline (preparations indicated for emergency supplemental treatment of acute hypotension or shock associated with various diseases or conditions)

March 27, 2018

Non-proprietary name

Adrenaline (preparations indicated for emergency supplemental treatment of acute hypotension or shock associated with various diseases or conditions)

Safety measure

Precautions should be revised in the package insert.

In the Contraindications section, the following language concerning antipsychotic agents with α -blocking actions including butyrophenones and phenothiazines, and α -blockers should be revised (revised language is underlined):

Patients receiving the following agents:

Antipsychotic agents with α -blocking actions including butyrophenones and phenothiazines, and α -blockers (except when used for emergency treatment of anaphylactic shock)

In the Contraindications for Co-administration subsection of the Interactions section, the following language concerning antipsychotic agents or α blockers should be revised (revised language is underlined):

Pharmaceuticals and Medical Devices Agency

Office of Safety I

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: safety.info@pmda.go.jp

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Antipsychotic agents with α -blocking actions (butyrophenones, phenothiazines, iminodibenzyls, zotepine, risperidone) and α blockers [Clinical symptoms and measures: Hypotension may occur due to adrenaline reversal. Adrenaline should not be co-administered with antipsychotic agents with α -blocking actions except when used for emergency treatment of anaphylactic shock.]

Pharmaceuticals and Medical Devices Agency

Office of Safety I

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: safety.info@pmda.go.jp